{"entity":{"id":"danatlas-pharmaceuticals","kind":"company","name":"Danatlas Pharmaceuticals","aka":["Danatlas Pharmaceuticals Co., Ltd","浙江丹擎药业科技有限公司","Beijing Danatlas"],"tldr":"Danatlas Pharmaceuticals is a Chinese company developing tablets that exploit weaknesses in how some cancer cells repair their DNA. Its lead drug, DAT-2645, is aimed at cancers with BRCA mutations, including ovarian cancer.","summary":"Zhejiang Danatlas Pharmaceutical Technology Co., Ltd. (Danatlas) is a clinical-stage Sino-foreign joint venture headquartered in the Qiantang pharmaceutical park in Hangzhou since August 2026, with offices in Beijing and Boston, according to the company. It builds targeted cancer drugs around synthetic lethality and transcriptional regulation; its founder, chairman and chief executive is Wenlai Zhou. DAT-2645 is a PARG inhibitor and DAT-1604 is a second oral candidate. Its first registered cancer trial, NCT06614751, a phase 1 dose-escalation and expansion study of DAT-2645 in advanced solid tumours with BRCA1/2 loss-of-function or other DNA damage repair defects, was posted on ClinicalTrials.gov in September 2024; a phase 1 study of DAT-1604 in advanced solid tumours (NCT06998173) followed in May 2025 and a phase 2 study of DAT-2645 in BRCA-mutated or HRD-positive ovarian cancer (NCT07652073) in June 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.danatlas.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of DAT-2645 (NCT06614751)","url":"https://clinicaltrials.gov/study/NCT06614751"},{"label":"ClinicalTrials.gov: phase 1 trial of DAT-1604 (NCT06998173)","url":"https://clinicaltrials.gov/study/NCT06998173"},{"label":"ClinicalTrials.gov: phase 2 trial of DAT-2645 in ovarian cancer (NCT07652073)","url":"https://clinicaltrials.gov/study/NCT07652073"}],"tags":[],"related":[],"cancers":["ovarian","breast-cancer"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the site footer reads 'Copyright 2019-2022 Beijing Danatlas', which is not a founding statement. The PARG mechanism of DAT-2645 is from the registry title; DAT-1604's mechanism was not stated. Financing not read. Read on 29 October 2026."],"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.danatlas.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/danatlas-pharmaceuticals/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}]}}